NEWS
- PROTAC Degraders in Clinical Trails: 2025 Update
- The Applications and Challenges of Lipid Nanoparticles
- Dual-Payload ADCs: A Revolutionary Leap in Targeted Cancer Therapy
- Send Your Published Paper Link with Our PEG Products, Get 20% OFF
- Antibody–Drug Conjugate Payloads: MMAE & MMAF
- Enhertu (Trastuzumab Deruxtecan): Magic ADC Drug
- Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment
- Three ADCs Expected To Be Approved In 2024-2025
- Antibody-drug Conjugates (ADCs) - Approvals by FDA/EMA/NMPA/PMDA
- FDA Approved Antibody-Drug Conjugates (ADCs) By 2025